(Q35005930)

5 August 2017

1 reference

title

Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens (English)

1 reference

5 August 2017

Rong-Fu Wang

1 reference

5 August 2017

publication date

1 October 2002

1 reference

5 August 2017

published in

Immunological Reviews

1 reference

5 August 2017

volume

188

1 reference

5 August 2017

page(s)

65-80

1 reference

A fresh look at tumor immunosurveillance and immunotherapy.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

EBV specific CTL: a model for immune therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Strategies for target cell recognition by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Immunity against cancer: lessons learned from melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

NKT cells - conductors of tumor immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

LAGE-1, a new gene with tumor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Degradation of cell proteins and the generation of MHC class I-presented peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

The proteasome: paradigm of a self-compartmentalizing protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

In vivo protein transduction: delivery of a biologically active protein into the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Cell-penetrating peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Coupling and uncoupling of tumor immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Serological identification of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

New paths in human cancer serology

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Identification of HLA-class-II-restricted epitopes of autoantigens in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Stabilization of beta-catenin by genetic defects in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Genomic analysis of metastasis reveals an essential role for RhoC

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Non-traditionally derived CTL epitopes: exceptions that prove the rules?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Selective proteasome inhibitors: modulators of antigen presentation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

The dendritic cell and human cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Intracellular Delivery of a Tat-eGFP Fusion Protein into Muscle Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Human tumor antigens for cancer vaccine development

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Role of dendritic cells in the induction and maintenance of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Cellular uptake of the tat protein from human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Intercellular trafficking and protein delivery by a herpesvirus structural protein

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Intercellular delivery of functional p53 by the herpesvirus protein VP22.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Genetic engineering of proteins with cell membrane permeability

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Tat-mediated delivery of heterologous proteins into cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

A unique tumor antigen produced by a single amino acid substitution

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Expression cloning of a protective Leishmania antigen

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Identification of a CD4+ T cell-stimulating antigen of pathogenic bacteria by expression cloning

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Human neoplasms elicit multiple specific immune responses in the autologous host

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Identification of autoantigen epitopes in MHC class II transgenic mice.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Inhibitors of mammalian G1 cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

A large glycoprotein lost from the surfaces of transformed cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18807.X

7 January 2021

10.1034/J.1600-065X.2002.18807.X

Identifiers

DOI

1 reference

5 August 2017

1 reference